期刊文献+
共找到2篇文章
< 1 >
每页显示 20 50 100
^(125)I放射性粒子条联合胆道支架与单纯胆道支架植入治疗恶性胆道梗阻的术后院内感染发生率及临床疗效的对照研究
1
作者 陈丽 陈敏江 +3 位作者 任建敏 谢艳茹 涂建飞 纪建松 《中华介入放射学电子杂志》 2024年第2期144-149,共6页
目的回顾性研究联合组[^(125)I(iodine)粒子条+胆道支架]及常规组(单纯胆道支架组)治疗恶性胆道梗阻(malignant biliary obstruction,MBO)的术后院内感染发生率及临床疗效。方法收集2019年4月至2022年6月期间因MBO就诊于温州医科大学附... 目的回顾性研究联合组[^(125)I(iodine)粒子条+胆道支架]及常规组(单纯胆道支架组)治疗恶性胆道梗阻(malignant biliary obstruction,MBO)的术后院内感染发生率及临床疗效。方法收集2019年4月至2022年6月期间因MBO就诊于温州医科大学附属第五医院(丽水市中心医院)且经皮肝穿刺胆道引流术(percutaneous transhepatic cholangial drainage,PTCD)序贯行胆道支架植入的128例(联合组70例、常规组58例)MBO患者的临床资料,所有病例PTCD术中获取胆汁,术后监测相关指标及不良事件情况,分析2组的术后院内感染发生率、术后总胆红素下降速率、支架通畅时间、不良事件发生率等。结果2组术后院内感染发生率比较,差异无统计学意义(8.5%∶8.6%;P>0.05);WBC(blood cell count)计数>10×10^(9)/L者较WBC计数≤10×10^(9)/L者,PTCD术中胆汁阳性率相对更高(48%∶26.2%;P<0.05);本研究共39例患者胆汁培养阳性,病原体构成比居前3位分别为肺炎克雷伯菌13例(32%)、大肠杆菌9例(22%)、铜绿假单胞菌7例(18%)。联合组术后总胆红素下降速率相对更快(7.1 d∶11.2 d;P<0.05);联合组及常规组的胆道支架中位通畅时间分别为5.9个月(95%CI:5~7个月)、2.6个月(95%CI:2~4个月),差异有统计学意义(P<0.05)。结论联合组未增加术后院内感染发生率,且临床疗效优于常规组,安全性高;PTCD术前WBC计数>10×109/L者胆汁阳性率更高,该类患者建议及早使用抗生素;胆道常见病原体前3位分别为肺炎克雷伯菌、大肠杆菌、铜绿假单胞菌。 展开更多
关键词 院内感染 胆道感染 胆道梗阻 胆道支架
原文传递
Expert consensus on the diagnosis and treatment of solid tumors with BRAF mutations
2
作者 Wenxian Wang Bin Lian +133 位作者 Chunwei Xu Qian Wang Ziming Li Nan Zheng Aijun Liu Jinpu Yu Wenzhao Zhong Zhijie Wang Yongchang Zhang Jingjing Liu Shirong Zhang Xiuyu Cai Anwen Liu Wen Li Lili Mao Ping Zhan Hongbing Liu Tangfeng Lv Liyun Miao Lingfeng Min Yu Chen Jingping Yuan Feng Wang Zhansheng Jiang Gen Lin Long Huang Xingxiang Pu Rongbo Lin Weifeng Liu Chuangzhou Rao Dongqing Lv Zongyang Yu Xiaoyan Li Chuanhao Tang Chengzhi Zhou Junping Zhang Junli Xue Hui Guo Qian Chu Rui Meng Xuewen Liu Jingxun Wu Rui Zhang Jin Zhou Zhengfei Zhu Yongheng Li Hong Qiu Fan Xia Yuanyuan Lu Xiaofeng Chen Jian Feng Rui Ge Enyong Dai Yu Han Weiwei Pan Fei Pang Xin Huang Meizhen Hu Qing Hao Kai Wang Fan Wu Binbin Song Bingwei Xu Liping Wang Youcai Zhu Li Lin yanru xie Xinqing Lin Jing Cai Ling Xu Jisheng Li Xiaodong Jiao Kainan Li Jia Wei Huijing Feng Lin Wang Yingying Du Wang Yao Xuefei Shi Xiaomin Niu Dongmei Yuan Yanwen Yao Jianhui Huang Yue Feng Yinbin Zhang Pingli Sun Hong Wang Mingxiang Ye Dong Wang Zhaofeng Wang Yue Hao Zhen Wang Bin Wan Donglai Lv Shengjie Yang Jin Kang Jiatao Zhang Chao Zhang Wenfeng Li Jianfei Fu Lizhi Wu Shijie Lan Juanjuan Ou Lin Shi Zhanqiang Zhai Yina Wang Bihui Li Zhang Zhang Ke Wang Xuelei Ma Zhongwu Li Zhefeng Liu Nong Yang Lin Wu Huijuan Wang Gu Jin Guansong Wang Jiandong Wang Hubing Shi Meiyu Fang Yong Fang Yuan Li Xiaojia Wang Jing Chen Yiping Zhang Xixu Zhu Yi Shen Shenglin Ma Biyun Wang Yong Song Zhengbo Song Wenfeng Fang Yuanzhi Lu Lu Si 《The Innovation》 EI 2024年第6期100-116,共17页
The BRAF gene is an important signaling molecule in human cells that is involved in the regulation of cell growth,differentiation,and survival.When the BRAF gene mutates,it can lead to abnormal activation of the signa... The BRAF gene is an important signaling molecule in human cells that is involved in the regulation of cell growth,differentiation,and survival.When the BRAF gene mutates,it can lead to abnormal activation of the signaling pathway,which promotes cell proliferation,inhibits cell apoptosis,and ultimately contributes to the occurrence and development of cancer.BRAF mutations are widely present in various cancers,including malignant melanoma,thyroid cancer,colorectal cancer,non-small cell lung cancer,and hairy cell leukemia,among others.BRAF is an important target for the treatment of various solid tumors,and targeted combination therapies,represented by BRAF inhibitors,have become one of the main treatment modalities for a variety of BRAF-mutation-positive solid tumors. 展开更多
关键词 BRAF DIAGNOSIS TREATMENT
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部